News
Novartis’ big bet on inclisiran nears fruition, as CHMP back...
Novartis’ near-$10 billion takeover of The Medicines Company last year was focused mainly on one asset – cholesterol-lowering drug inclisiran – and the Swiss pharma is now a step closer to
